司美格鲁肽在肥胖合并心衰患者中的心血管结局:SELECT试验预设分析
SELECT试验是一项在41个国家进行的随机、双盲、多中心、安慰剂对照、事件驱动的3期试验,纳入年龄≥45岁、BMI≥27 kg/m²且已确诊心血管疾病的成人,随机分配至司美格鲁肽2.4mg每周皮下注射(16周内递增至目标剂量)或安慰剂。预设分析显示,在17 604例患者中,4286例(24.3%)有心衰病史;司美格鲁肽在有或无(或无)心衰病史患者中均改善所有结局指标(MACE的HR 0.72,95%CI 0.60-0.87;心衰复合终点0.79,0.64-0.98;心血管死亡0.76,0.59-0.97;全因死亡0.81,0.66-1.00;所有交互作用P>0.19),且在不同心衰亚型中均一致。作者认为,这些发现可能促进处方并改善该患者群体的临床结局。
要点
- 在超重或肥胖合并动脉粥样硬化性心血管疾病患者中,无论有无心衰病史,司美格鲁肽2.4mg每周皮下注射均降低MACE(HR 0.72,95%CI 0.60-0.87)和心衰复合终点(HR 0.79,95%CI 0.64-0.98)。
- 心衰病史亚组分析显示,司美格鲁肽降低心血管死亡(HR 0.76,95%CI 0.59-0.97)和全因死亡(HR 0.81,95%CI 0.66-1.00),所有交互作用P>0.19。
- 射血分数降低的心衰(HFrEF)组MACE的HR为0.65(95%CI 0.49-0.87),射血分数保留的心衰(HFpEF)组为0.69(95%CI 0.51-0.91);心衰复合终点的HR分别为0.79(0.58-1.08)和0.75(0.52-1.07)。
- 在年龄、性别、BMI、纽约心脏协会(NYHA)心功能分级和利尿剂使用等基线特征方面,MACE和心衰复合终点的获益无显著差异。
- 无论心衰亚型如何,司美格鲁肽组的严重不良事件发生率低于安慰剂组。
适用人群与场景
- 年龄≥45岁、BMI≥27 kg/m²且已确诊心血管疾病的成人。
- 纳入分析的患者按有无心衰病史分层,心衰病史由研究者定义;其中HFpEF 2273例(53.0%),HFrEF 1347例(31.4%),未分类心衰666例(15.5%)。
处置流程与药物剂量
- 司美格鲁肽:每周皮下注射一次,在16周内递增至目标剂量2.4mg。
研究设计与关键结果
- SELECT试验为随机、双盲、多中心、安慰剂对照、事件驱动的3期试验,在41个国家进行,共纳入17 604例患者,平均年龄61.6岁(SD 8.9),平均BMI 33.4 kg/m²(5.0),司美格鲁肽组8803例(50.0%),安慰剂组8801例(50.0%)。
- 4286例(24.3%)有心衰病史:HFpEF 2273例(53.0%),HFrEF 1347例(31.4%),未分类心衰666例(15.5%)。
- 在有 vs 无(或无)心衰病史的患者中,司美格鲁肽对比安慰剂的HR分别为:MACE 0.72(95%CI 0.60-0.87);心衰复合终点0.79(95%CI 0.64-0.98);心血管死亡0.76(95%CI 0.59-0.97);全因死亡0.81(95%CI 0.66-1.00);所有交互作用P>0.19。
- HFrEF组:MACE的HR 0.65(95%CI 0.49-0.87),心衰复合终点HR 0.79(95%CI 0.58-1.08);HFpEF组:MACE的HR 0.69(95%CI 0.51-0.91),心衰复合终点HR 0.75(95%CI 0.52-1.07)。
- 在年龄、性别、BMI、NYHA心功能分级和利尿剂使用方面,MACE和心衰复合终点的获益无显著差异。
- 无论心衰亚型如何,司美格鲁肽组的严重不良事件发生率低于安慰剂组。
证据类型、等级与局限
- 研究类型:随机、双盲、多中心、安慰剂对照、事件驱动的3期试验的预设分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在超重或肥胖合并动脉粥样硬化性心血管疾病患者中,无论有无临床心衰或心衰亚型,司美格鲁肽2.4mg每周皮下注射可降低MACE和心衰复合终点,这些发现可能促进处方并改善该患者群体的临床结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure.
METHODS: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597.
FINDINGS: Between Oct 31, 2018, and March 31, 2021, 17 604 patients with a mean age of 61·6 years (SD 8·9) and a mean BMI of 33·4 kg/m2 (5·0) were randomly assigned to receive semaglutide (8803 [50·0%] patients) or placebo (8801 [50·0%] patients). 4286 (24·3%) of 17 604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53·0%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31·4%) had heart failure with reduced ejection fraction, and 666 (15·5%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60-0·87 for MACE; 0·79, 0·64-0·98 for the heart failure composite endpoint; 0·76, 0·59-0·97 for cardiovascular death; and 0·81, 0·66-1·00 for all-cause death; all pinteraction>0·19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0·65, 95% CI 0·49-0·87 for MACE; 0·79, 0·58-1·08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0·69, 0·51-0·91 for MACE; 0·75, 0·52-1·07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype.
INTERPRETATION: In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2·4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group.
FUNDING: Novo Nordisk.
参考来源
- Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024. PMID: 39181597. doi:10.1016/S0140-6736(24)01498-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。